ALKERMES | ALKS - 税前利润

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.56B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	税前利润	更改		日
AbbVie	USD 7.61B		2.04B	2026-06
Acadia Pharmaceuticals	USD 46.47M		42.49M	2026-06
ALKERMES	USD -61.93M		122.3M	2026-03
Amgen	USD 2.08B		570M	2026-03
Biogen	USD 647.3M		269.6M	2026-06
BioMarin Pharmaceutical	USD 141.2M		168.36M	2026-03
Bristol-Myers Squibb	USD 4.99B		1.75B	2026-06
Coherus Biosciences	USD -46.35M		90.86M	2025-12
Eli Lilly	USD 8.85B		583.8M	2026-03
Gilead Sciences	USD -7.53B		10.11B	2026-06
Heron Therapeutics	USD -2.95M		14.54M	2025-12
Ionis Pharmaceuticals	USD -114M		21M	2026-06
J&J	USD 8.66B		839M	2026-06
Merck	USD -3.53B		6.95B	2026-03
Minerva Neurosciences	USD 22.51M		30.74M	2024-09
Nektar Therapeutics	USD -43.09M		8.39M	2026-03
Neurocrine Biosciences	USD 246.8M		7.4M	2026-03
Otsuka Holdings	JPY 130.23B		54.96B	2026-03
Pfizer	USD -653M		5.84B	2026-06
Regeneron Pharmaceuticals	USD 1.53B		696.6M	2026-06
Vertex Pharmaceuticals	USD 1.39B		138.9M	2026-06